Wednesday, March 25, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Fauci and WHO Director-General disagree on COVID booster programs

As the omicron variant surges throughout the United States, health officials are urging Americans to get their Covid booster vaccines when eligible. However, during press briefings last week, America’s top infectious disease specialist, Dr. Anthony Fauci, and the World Health Organization (Who) Director-General Dr. Tedros Adhanom Ghebreyesus do not appear to see eye to eye when it comes to booster vaccination programs during the fight against Covid.

“No country can boost its way out of the pandemic,” Dr. Tedros Adhanom Ghebreyesus said during a briefing.

The WHO Director-General criticized blanket COVID-19 booster programs that are being rolled out while other countries struggle to get vaccine supplies. Ghebreyesus said in the briefing that only half of WHO’s Member States have met the target of vaccinating 40 percent of their populations by the end of the year because of unequal distribution of global supply.

Source: Fox News

https://www.foxnews.com/health/fauci-who-director-general-disagree-covid-booster-programs

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!